Manufacturer of Controlled Substances; Notice of Application, 73359-73360 [E7-25049]

Download as PDF 73359 Federal Register / Vol. 72, No. 247 / Thursday, December 27, 2007 / Notices DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Importer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 31, 2007, Innovacon, Inc., 4106 Sorrento Valley Boulevard, San Diego, California 92121, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on November 7, 2007, Johnson Matthey, Inc., Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II: Drug Drug Schedule Tetrahydrocannabinols (7370). 3,4– Methylenedioxymethamphetamine (MDMA) (7405). Heroin (9200) .................. Cocaine (9041) ............... Hydromorphone (9150) ... Hydrocodone (9193) ....... Levorphanol (9220) ......... Methadone (9250) .......... Morphine (9300) ............. Thebaine (9333) ............. Phenylacetone (8501) .................. Raw Opium (9600) ....................... Concentrate of Poppy Staw (9670). I I I II II II II II II II mstockstill on PROD1PC66 with NOTICES The company plans to utilize small quantities of controlled substances to produce drugs of abuse tests. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 25, 2008. Dated: December 17, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–25053 Filed 12–26–07; 8:45 am] BILLING CODE 4410–09–P VerDate Aug<31>2005 18:00 Dec 26, 2007 Schedule Jkt 214001 II II II The company plans to import the listed controlled substances as raw materials for use in the manufacture of bulk controlled substances for distribution to its customers. No comments, objections, or requests for any hearings will be accepted on any application for registration or reregistration to import crude opium, poppy straw, concentrate of poppy straw, or coca leaves. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative/ODL, Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than January 28, 2008. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR § 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. Dated: December 18, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–25043 Filed 12–26–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 7, 2007, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Tetrahydrocannabinols (7370). Dihydromorphine (9145) Difenoxin (9168) ............. Propiram (9649) .............. Amphetamine (1100) ...... Methamphetamine (1105) Methylphenidate (1724) .. Nabilone (7379) .............. Cocaine (9041) ............... Codeine (9050) ............... Dihydrocodeine (9120) ... Oxycodone (9143) .......... Hydromorphone (9150) ... Ecgonine (9180) ............. Hydrocodone (9193) ....... Meperidine (9230) ........... Methadone (9250) .......... Methadone intermediate (9254). Morphine (9300) ............. Thebaine (9333) ............. Oxymorphone (9652) ...... Noroxymorphone (9668) Alfentanil (9737) .............. Remifentanil (9739) ........ Sufentanil (9740) ............ Fentanyl (9801) ............... E:\FR\FM\27DEN1.SGM 27DEN1 Schedule I I I I II II II II II II II II II II II II II II II II II II II II II II 73360 Federal Register / Vol. 72, No. 247 / Thursday, December 27, 2007 / Notices The company plans to manufacture the listed controlled substances in bulk for sale to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 25, 2008. Dated: December 17, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–25049 Filed 12–26–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer Of Controlled Substances; Notice Of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 6, 2007, Noramco Inc., Division of Ortho, McNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: mstockstill on PROD1PC66 with NOTICES Drug Schedule Codeine-N-oxide (9053) Morphine-N-oxide (9307) Dihydromorphine (9145) Codeine (9050) ............... Dihydrocodeine (9120) ... Oxycodone (9143) .......... Hydromorphone (9150) ... Hydrocodone (9193) ....... Morphine (9300) ............. Thebaine (9333) ............. Opium, raw (9600) .......... Opium extracts (9610) .... Opium fluid extract (9620). Opium tincture (9630) ..... Opium, powdered (9639) Opium, granulated (9640) Poppy Staw (9650) ......... VerDate Aug<31>2005 I I II II II II II II II II II II II Schedule Oxymorphone (9652) ...... Alfentanil (9737) .............. Sufentanil (9740) ............ Carfentanil (9743) ........... Fentanyl (9801) ............... II II II II II The company plans to bulk manufacture the above listed controlled substances for sale and distribution to manufacturers for product development and formulation. Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 25, 2008. Dated: December 17, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–25045 Filed 12–26–07; 8:45 am] BILLING CODE 4410–09–P Drug Enforcement Administration Importer of Controlled Substances; Notice of Application This is notice that on November 6, 2007, Noramco Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II: Schedule Raw Opium (9600) ......... Concentrate of Poppy Straw (9670). II II The company plans to import the listed controlled substances to manufacture other controlled substances. As noted in a previous notice published in the Federal Register on Jkt 214001 September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. Dated: December 17, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–25054 Filed 12–26–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 12, 2007, Orasure Technologies, Inc., Lehigh University, Seeley G MuddBuilding 6, 220 East First Street, Bethlehem, Pennsylvania 18015, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug DEPARTMENT OF JUSTICE Drug II II II II 19:40 Dec 26, 2007 Drug PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 Tetrahydrocannabinols (THC) (7370). 4–Methoxyamphetamine (7411). Normorphine (9313) ........ Amphetamine (1100) ...... Methamphetamine (1105) Cocaine (9041) ............... Oxycodone (9143) .......... Hydromorphone (9150) ... Benzoylecgonine (9180) Hydrocodone (9193) ....... Meperidine (9230) ........... Methadone (9250) .......... Morphine (9300) ............. Schedule I I I II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk to manufacture controlled substance derivatives. These derivatives will be used in diagnostic products created specifically for internal use only. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). E:\FR\FM\27DEN1.SGM 27DEN1

Agencies

[Federal Register Volume 72, Number 247 (Thursday, December 27, 2007)]
[Notices]
[Pages 73359-73360]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-25049]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 7, 2007, Johnson 
Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, 
West Deptford, New Jersey 08066-1742, made application by renewal to 
the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
Dihydromorphine (9145).....................  I
Difenoxin (9168)...........................  I
Propiram (9649)............................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Nabilone (7379)............................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Ecgonine (9180)............................  II
Hydrocodone (9193).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Noroxymorphone (9668)......................  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------


[[Page 73360]]

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administrator, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than February 25, 2008.

    Dated: December 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-25049 Filed 12-26-07; 8:45 am]
BILLING CODE 4410-09-P